UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549










FORM 10-K/A



(Amendment No. 1)










(Mark One)



| | x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
| | - | ------------------------------------------------------------------------------------



For the fiscal year ended December 31,
2016



or



| |  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
| | - | ----------------------------------------------------------------------------------------



For the transition period from   
to



Commission file number 001-35622








Albany Molecular Research, Inc.

(Exact name of registrant as specified in
its charter)



|Delaware                                 |  | 14-1742717         
|---------------------------------------- |  | -------------------
|(State or other jurisdiction of          |  | (I.R.S. Employer   
|incorporation or organization)           |  | Identification No.)
|                                         |  |                    
|26 Corporate Circle                      |  |                    
|Albany, New York                         |  | 12212              
|(Address of principal executive offices) |  | (zip code)         



(518) 512-2000

(Registrant’s telephone number, including
area code)

Securities registered pursuant to Section 12(b) of
the Act:



|Title of each class                    |  | Name of exchange on which registered
|-------------------------------------- |  | ------------------------------------
|Common Stock, par value $.01 per share |  | The NASDAQ Stock Market LLC         
|                                       |  |                                     



Securities registered pursuant to Section 12(g) of
the Act:

None

(Title of Each Class)



Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesoNox



Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
YesoNox



Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YesxNo ̈



Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes   x    No ̈



Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.x



Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting
company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting
company” in 12b-2 of the Exchange Act



| ̈Large accelerated filer |  | xAccelerated
filer |  |  ̈Non-accelerated filer |  |  ̈ Smaller reporting company
|------------------------ |  | ------------------ |  | ---------------------- |  | ---------------------------
| ̈Emerging growth company |  |                    |  |                        |  |                            



Indicate
by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesoNox



If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  YesoNoo





The aggregate market
value of the Registrant’s Common Stock held by non-affiliates of the Registrant on June 30, 2016 was approximately $355.4
million based upon the closing price per share of the Registrant’s Common Stock as reported on the Nasdaq Global Market on
June 30, 2016. Shares of Common Stock held by each officer and director and by each person who owns 10% or more of the outstanding
Common Stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is
not necessarily a conclusive determination for other purposes. As of February 28, 2017, there were 42,940,675 outstanding shares
of the Registrant’s Common Stock, excluding treasury shares of 5,669,707.













DOCUMENTS INCORPORATED BY REFERENCE



The information required
pursuant to Part III of this report is incorporated by reference from the Company’s definitive proxy statement, relating
to the annual meeting of stockholders to be held on or around May 31, 2017, pursuant to Regulation 14A to be filed with the Securities
and Exchange Commission.















Explanatory
Note



On
March 16, 2017, Albany Molecular Research, Inc. (the “Company”) filed its Annual Report on Form 10-K
for the fiscal year ended December 31, 2016 (the “Form 10-K”).



This
Form 10-K/A filing is made solely for the purpose of correcting a clerical error in Schedule II – Valuation and Qualifying
Accounts to conform certain information set forth therein to the numbers that were correctly reported in the Notes to the Consolidated
Financial Statements in the Form 10-K. No other items in the Form 10-K are being amended hereby.











ITEM 15. EXHIBITS AND FINANCIAL
STATEMENT SCHEDULES



(a) (2)	Financial Statement Schedules





ALBANY MOLECULAR RESEARCH, INC.
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2016, 2015 and 2014



|Description                                |  | Balance at Beginning of  Period |        |  | Acquisitions |   |       | (Reversal of)/
 Charge to Cost and Expenses |  |   | DeductionsCharged toReserves/
Adjustment |   |  | Balance at End of Period |       
|------------------------------------------ |  | ------------------------------- | ------ |  | ------------ | - | ----- | ------------------------------------------- |  | - | ---------------------------------------- | - |  | ------------------------ | ------
|(in thousands)                             |  |                                 |        |  |              |   |       |                                             |  |   |                                          |   |  |                          |       
|Allowance for doubtful accounts receivable |  |                                 |        |  |              |   |       |                                             |  |   |                                          |   |  |                          |       
|2016                                       |  | $                               | 1,096  |  |              | $ | 557   |                                             |  | $ | 2,777                                    |   |  | $                        | (700  
|2015                                       |  | $                               | 1,274  |  |              | $ | —     |                                             |  | $ | 1,289                                    |   |  | $                        | (1,467
|2014                                       |  | $                               | 815    |  |              | $ | 414   |                                             |  | $ | 343                                      |   |  | $                        | (298  
|                                           |  |                                 |        |  |              |   |       |                                             |  |   |                                          |   |  |                          |       
|Deferred tax asset valuation allowance     |  |                                 |        |  |              |   |       |                                             |  |   |                                          |   |  |                          |       
|2016                                       |  | $                               | 10,947 |  |              | $ | 1,152 |                                             |  | $ | 24,486                                   |   |  | $                        | (3,336
|2015                                       |  | $                               | 20,895 |  |              | $ | —     |                                             |  | $ | (9,948                                   | ) |  | $                        | —     
|2014                                       |  | $                               | 21,403 |  |              | $ | —     |                                             |  | $ | (508                                     | ) |  | $                        | —     
|                                           |  |                                 |        |  |              |   |       |                                             |  |   |                                          |   |  |                          |       









SIGNATURES



Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.



|Dated: May 9, 2017 | Albany Molecular Research, Inc.
|------------------ | -------------------------------
|                   |                                
|                   |                                
|                   | By:                            
|                   |                                
|                   |